{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-055272","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.402923+00:00","generated_at":"2026-06-26T01:11:15.606265+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rigel Q1 net loss $27.4M vs prior-year net income; TAVALISSE sales up 31%","bullets":["Net loss of $27.4M ($0.16/sh) vs net income of $39.5M ($0.23/sh) in Q1 2021.","Total revenues $16.7M: TAVALISSE net product sales $16.2M (+31% YoY); contract revenues $0.5M.","Cash and short-term investments $107.5M at March 31, down from $125.0M at Dec 31, 2021.","FORWARD Phase 3 wAIHA trial topline data expected mid-2022; potential first-to-market therapy if approved.","COVID-19 fostamatinib trial enrolled 268 of 308 patients; evaluating completion strategies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-055272","json":"https://secwatch.observer/filing/0001104659-22-055272.json","markdown":"https://secwatch.observer/filing/0001104659-22-055272.md","text":"https://secwatch.observer/filing/0001104659-22-055272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922055272/0001104659-22-055272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922055272/tm2214228d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:11:15.606265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}